Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00301080 · ClinicalTrials.gov registry record · Phase 3

D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain

A Phase 3 study, sponsored by Northwestern University.

Terminated
Registry status
Phase 3
Development phase
7
Enrollment target

NCT00301080 is a Phase 3 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 7 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00301080, a Phase 3 study, was terminated before completion, sponsored by Northwestern University.

TERMINATED
Registry status
Phase 3
Development phase
7 participants
Enrollment target

Study Summary

D-cycloserine may help lessen pain and other symptoms of peripheral neuropathy caused by chemotherapy. It is not yet known whether D-cycloserine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy. This randomized, double-blind, placebo-controlled clinical trial was designed to study D-cycloserine at 2 different doses to see how well each works compared to the other and to a placebo in treating cancer patients with peripheral neuropathy caused by chemotherapy.

Interventions

  • OTHER Placebo
  • DRUG D-cycloserine

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2006-02
Est. Completion 2008-05
Phase Phase 3

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT00301080

The ClinicalTrials.gov registry entry for NCT00301080 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00301080 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00301080 about?

NCT00301080 is a clinical study titled "D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain". D-cycloserine may help lessen pain and other symptoms of peripheral neuropathy caused by chemotherapy. It is not yet known whether D-cycloserine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy. This randomized, double-blind, placebo-controlled clinical tria...

What is the current status of trial NCT00301080?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2006-02. Estimated completion is 2008-05.

What interventions are being tested in trial NCT00301080?

The interventions under investigation include: Placebo (OTHER), D-cycloserine (DRUG).

Who is sponsoring clinical trial NCT00301080?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.